$6.35
Sight Sciences is a medical devices business based in the US. Sight Sciences shares (SGHT) are listed on the NASDAQ and all prices are listed in US Dollars. Sight Sciences employs 214 staff and has a trailing 12-month revenue of around $79.4 million.
Our top picks for where to buy Sight Sciences stock
How to buy Sight Sciences stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – SGHT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Sight Sciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Sight Sciences stock price (NASDAQ: SGHT)
Use our graph to track the performance of SGHT stocks over time.Sight Sciences shares at a glance
Latest market close | $6.35 |
---|---|
52-week range | $1.04 - $8.45 |
50-day moving average | $6.76 |
200-day moving average | $5.31 |
Wall St. target price | $7.38 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.06 |
Is it a good time to buy Sight Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sight Sciences price performance over time
Historical closes compared with the close of $6.35 from 2024-09-06
1 week (2024-08-30) | -6.20% |
---|---|
1 month (2024-08-07) | 15.25% |
3 months (2024-06-07) | -7.43% |
6 months (2024-03-07) | 38.04% |
1 year (2023-09-07) | 1.11% |
---|---|
2 years (2022-09-07) | -16.56% |
3 years (2021-09-07) | 33.42 |
5 years (2019-09-03) | N/A |
Sight Sciences financials
Revenue TTM | $79.4 million |
---|---|
Gross profit TTM | $59 million |
Return on assets TTM | -19.36% |
Return on equity TTM | -44.01% |
Profit margin | -65.9% |
Book value | $2.03 |
Market Capitalization | $340.6 million |
TTM: trailing 12 months
Sight Sciences share dividends
We're not expecting Sight Sciences to pay a dividend over the next 12 months.
Sight Sciences share price volatility
Over the last 12 months, Sight Sciences's shares have ranged in value from as little as $1.04 up to $8.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sight Sciences's is 2.745. This would suggest that Sight Sciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Sight Sciences's beta into context you can compare it against those of similar companies.
- Bausch Health Companies (BHC.US): 0.77
- Glaukos (GKOS.US): 1.061
- Harrow Health (HROW.US): 0.745
Sight Sciences overview
Sight Sciences, Inc. , an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc.
Frequently asked questions
What percentage of Sight Sciences is owned by insiders or institutions?Currently 20.509% of Sight Sciences shares are held by insiders and 50.892% by institutions. How many people work for Sight Sciences?
Latest data suggests 214 work at Sight Sciences. When does the fiscal year end for Sight Sciences?
Sight Sciences's fiscal year ends in December. Where is Sight Sciences based?
Sight Sciences's address is: 4040 Campbell Avenue, Menlo Park, CA, United States, 94025 What is Sight Sciences's ISIN number?
Sight Sciences's international securities identification number is: US82657M1053
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question